
CANbridge gets rights to Aveo's mAb AV203; deal terminated
Executive Summary
Aveo Pharmaceuticals Inc. (also known as Aveo Oncology) granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its anticancer monoclonal antibody AV203 worldwide excluding the US, Canada, and Mexico. Biogen Idec previously held an option to the project under a 2009 deal, but waived its option in 2014.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com